HC Wainwright & Co. reiterates Buy rating on Adagene, $7 price target

HC Wainwright & Co. reiterated a Buy rating on Adagene with a $7 price target, implying a 239.8% upside from the Oct 16 close of $2.06. The firm cited positive clinical developments, including progress in Phase 1 studies for ADG138 and ADG126, and upcoming data readouts for muzastotug in combination with pembrolizumab.

Original reporting
Published Oct 19, 2026, 10:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 10:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. reiterates Buy rating on Adagene, $7 price target — source image
Decision brief

The 30-second read

Low
01

Why it matters

The rating change adds a short‑term bullish bias, but the lack of efficacy data tempers the upside.

02

Market read

Analyst upgrade with a high price target may attract short‑term buying interest in ADGE.

03

What to watch

Trial enrollment timelines and regulatory hurdles could delay any upside.

Relevance 6/10Novelty 6/10Timing: today

Background

Adagene is a clinical‑stage biotech developing antibody‑drug conjugates. The analyst note highlights early trial activity and a new $7 price target.

Market effects

Positive sentiment may spill to other early‑stage biotech stocks.

Limited to US biotech sector.

Minor, confined to investors tracking clinical‑trial pipelines.

Counterpoint

Without data readouts, the upgrade may be premature; risk of disappointment remains.

Key entities

  • HC Wainwright & Co.

    Equity research firm that issued the Buy rating and price target.

  • Adagene

    Biotech firm developing ADG138 and ADG126 (muzastotug).

Related articles

$ADAGLowAI 8/10

Adagene completes enrollment in phase 2 trial of muzastotug

Adagene Inc. (ADAG) completed enrollment in a Phase 2 trial of muzastotug, an anti-CTLA-4 antibody therapy, combined with Merck’s KEYTRUDA for late-line colorectal cancer. The trial enrolled 60 patients, with results expected in early 2027. The FDA confirmed Phase 3 trial design elements, and Sanofi invested in the trial. Muzastotug has FDA Fast Track designation.